Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5435_Библиотеки_им_академика_М_И_Перельмана
.pdf
– Virtual screening: Cheminformatics methods can be used to virtually screen large
chemical libraries against target proteins or biological assays. QSAR models can be
employed to predict the activity of compounds against a particular target based on
their chemical structures. This allows researchers to prioritize and select a smaller
set of compounds for experimental testing, saving time and resources.
– Structure-based drug design: Cheminformatics tools can aid in the design of
new compounds based on the three-dimensional structure of a target protein.
QSAR models can be used to predict the activity of these designed compounds,
guiding the selection and optimization of lead candidates.
– ADME-Tox prediction: Cheminformatics and QSAR models can be utilized to pre-
dict the absorption, distribution, metabolism, excretion, and toxicity (ADME-Tox)
properties of compounds. These predictions help identify potential issues early in
the drug discovery process and guide lead optimization e fforts towards com-
pounds with favorable ADME-Tox profiles.
– SAR analysis: Structure-activity relationship (SAR) analysis involves the explora-
tion of the relationship between the chemical structure of a compound and its bio-
logical activity. QSAR models can provide insights into the key structural features
that contribute to the activity of a molecule. This knowledge can guide medicinal
chemists in modifying lead compounds to enhance their activity, selectivity, and
other desirable properties.
– Property prediction and optimization: Cheminformatics tools, combined with
QSAR models, can predict various molecular properties such as solubility, lipophi-
licity, and stability. These predictions aid in the optimization of lead compounds
by selecting or designing molecules with improved properties.
Overall, cheminformatics and QSAR play crucial roles in lead discovery by facilitating
compound selection, virtual screening, molecular design, property prediction, and op-
timization. They provide valuable insights and guide medicinal chemists in the itera-
tive process of lead identification and optimiz ation, ultimately accelerating the drug
discovery pipeline.
2.2 Summary
Lead-hit-based methods have proven to be valuable tools in the field of drug design.
These methods involve the identification and optimization of lead compounds that
have the potential to become effective drugs. Lead-hit-based approaches offer several
advantages, including the ability to rapidly screen large compound libraries and the
potential for SAR analysis.
One of the key strengths of lead-hit-based methods is their ability to efficiently iden-
tify compounds with promising biological activity. By screening large libraries of com-
44 Gita Chawla and Tathagata Pradhan
https://t.me/med1917
pounds against a specific target, researchers can quickly identify hits that show potential
for further development. These hits can then be optimized through medicinal chemistry
techniques to improve their potency, selectivity, and other desirable properties.
Lead-hit-based methods also enable researchers to explore the SAR of the identi-
fied hits. By systematically modifying the chemical structure of the lead compounds
and evaluating their biologica l activity, researchers can gain valuable in sights into
the key molecular interactions required for optimal drug-target binding. This knowl-
edge can guide the design of more potent and selective compounds.
Moreover, lead-hit-based methods can be applied in a variety of drug discovery
scenarios, including both t arget- based and phenotypic screening approaches. They
provide a flexible and adaptable framework for identifying potential drug candidates,
allowing researchers to prioritize compounds with the most promising profiles for
further development.
However, it is important to note that lead-hit-based methods also have some limi-
tations. The identified leads may require extensive optimization to achieve the de-
sired properties, which can be time-consuming and resource-intensive. Furthermore,
the effectiveness of lead-hit-based methods heavily relies on the quality and diversity
of the compound libraries used for screening. The availability of high-quality libraries
with diverse chemical space is crucial for successful lead-hit identification.
In summary, lead-hit-based methods have demonstrated their value in drug design
by enabling efficient identification and optimization of lead compounds. They provide a
systematic approach for exploring the SAR and offer flexibility in different drug discov-
ery scenarios. While they have limitations, lead-hit-based methods remain an important
tool in the pharmaceutical industry’s quest to develop new and effective drugs.
2.3 Future directions
The future of lead-hit based methods, including HTS, virtual screening, phenotypic
screening, and natural product screening, holds promising directions that capitalize
on technological advancements and innovative approaches. These methods are poised
to reshape drug discovery by enhancing efficiency, accuracy, and our understanding
of complex biological systems. HTS, a cornerstone of lead discovery, is set to benefit
from advanced automation, enabling the screening of larger compound libraries with
unprecedented speed. Innovations in microfluidics and 3D-printed microplates could
lead to more cost-effective and high-throughput assays, while integrated robotics and
AI-driven data analysis will expe dite hit identification. Virtual screening, leveraging
computational modeling, is on the brink of transformation due to the surge in com-
puting power and algorithms. AI and machine learning algorithms will enhance pre-
dictive accuracy, helping prioritize compounds for screening and minimizing false
positives. Coupled with experimental validation, virtual screening will become an
2 Lead-hit-based methods for drug design and ligand identification 45
https://t.me/med1917
even more integral part of lead discovery. Phenotypic screening, with its focus on ob-
servable cellular responses, will benefit from advancements in 3D cell culture models
and organoids. These systems offer a closer representation of in vivo conditions, en-
hancing the physiological relevance of hits. Coupling phenotypic screening with tech-
niques like CRISPR-Cas9 gene editing will uncover novel drug targets and pathways.
Natural product screening, once overshadowed by synthetic compounds, is experienc-
ing a revival. Innovative extraction and modification techniques will unlock the vast
potential of natural sources, leading to the discovery of unique bioactive molecules.
Advancements in structural biology, including cryo-electron microscopy, will aid in
understanding the interactions between natural compounds and their targets.
Target-agnostic screening approaches will gain momentum, allowing for the iden-
tification of hits based on desired phenotypic outcomes. This approach will uncover
new pathways and therapeutic avenues, particularly in complex diseases with poorly
understood mechanisms.
Repurposing existing drugs and designing compounds with polypharmacological
properties will continue to gain traction. With the aid of AI-driven databases and
omics data integration, this strategy could uncover unexpected therapeutic applica-
tions and accelerate drug development timelines.
The incorporation of multi-omics data, encompassing genomics, proteomics, and
metabolomics, will provide a holistic view of compound effects, aiding hit validation
and mechanism elucidation. Additionally, biosensor technologies and label-free as-
says will drive the development of high-content screening platforms, offering rich
and context-rich data.
Ethnopharmacology and traditional medicine will serve as a valuable resource
for lead discovery. Exploring indigenous knowledge and remedie s from diverse cul-
tures could unveil novel bioactive compounds with therapeutic potential.
In conclusion, the future of lead-hit-based methods is characterized by integration,
innovation, and int erdisciplinary collaboration. HTS, virtual sc reening, p henotypic
screening, and natural product screening will be transformed by AI, automation, ad-
vanced analytics, and novel experimental models. These developments will usher in a
new era of drug discovery, where targeted and effective therapies emerge more rapidly,
addressing unmet medical needs and improving patient outcomes.
Abbreviations
HTS High-throughput screening
FBDD Fragment-based drug design
SAR Structure–activity relationships
HIV Human immunodeficiency virus
SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2
K
d
Equilibrium dissociation constant
46 Gita Chawla and Tathagata Pradhan
https://t.me/med1917
BCL-2 B-cell lymphoma 2
PARP Poly(ADP-ribose) polymerases
BRCA Breast cancer gene
mTOR Mammalian target of rapamycin
ATP Adenosine triphosphate
K
i
Inhibition constant
References
[1] Zhou, S. F., & Zhong, W. Z. Drug design and discovery: Principles and applications. Molecules, 2017,
22(2), MDPI 279.
[2] Mandal, S., & Mandal, S. K. Rational drug design. European Journal of Pharmacology, 2009,
625(1–3), 90–100.
[3] Silverman, R. B., & Holladay, M. W. The Organic Chemistry of Drug Design and Drug Action, 3rd
Edition, 2014, Academic press: San diego, CA, USA.
[4] Sadybekov, A. V., & Katritch, V. Computational approaches streamlining drug discovery. Nature,
2023, 616(7958), 673–685.
[5] Jabalia, N., et al. In silico approach in drug design and drug discovery: An update. Innovations and
Implementations of Computer Aided Drug Discovery Strategies in Rational Drug Design, 2021, (pp.
245–271), Springer Nature Singapore Pte Ltd.
[6] Keserű, G. M., & Makara, G. M. Hit discovery and hit-to-lead approaches. Drug Discovery Today,
2006, 11(15–16), 741 – 748.
[7] Goodnow, R. A., Jr. Hit and lead identification: Integrated technology-based approaches. Drug
Discovery Today: Technologies, 2006, 3(4), 367–375.
[8] Bleicher, K. H., et al. Hit and lead generation: Beyond high-throughput screening. Nature Reviews
Drug Discovery, 2003, 2(5), 369–378.
[9] Bassani, D., & Moro, S. Past, present, and future perspectives on computer-aided drug design
methodologies. Molecules, 2023, 28(9), 3906.
[10] Lloyd, M. D. High-throughput screening for the discovery of enzyme inhibitors. Journal of Medicinal
Chemistry, 2020, 63(19), 10742–10772.
[11] Henkes, M., Van der Kuip, H., & Aulitzky, W. E. Therapeutic options for chronic myeloid leukemia:
Focus on imatinib (Glivec®, Gleevec™). Therapeutics and Clinical Risk Management, 2008, 4(1),
163–187.
[12] Magano, J. Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and
oseltamivir phosphate (Tamiflu) for the treatment of influenza. Chemical Reviews, 2009, 109(9),
4398–4438.
[13] Follmann, M., et al. An approach towards enhancement of a screening library: The next generation
library initiative (NGLI) at Bayer – Against all odds?. Drug Discovery Today, 2019, 24(3), 668–672.
[14] Zhang, J., & Crawford, J. Rivaroxaban (Xarelto): A factor Xa Inhibitor for the treatment of thrombotic
events. Modern Drug Synthesis, 2010, (191–205), John Wiley & Sons, Inc.
[15] Efremov, I. V., & Erlanson, D. A. Fragment‐based lead generation. Lead Generation, 2016, (pp.
133–158), Wiley-VCH Verlag GmbH & Co. KGaA, Boschstr: Weinheim, Germany, 12, 69469.
[16] Bharatam, P. V. Computer-aided drug design. Drug Discovery and Development: From Targets and
Molecules to Medicines, 2021, (pp. 137–210), Springer: Singapore.
[17] Sabe, V. T., et al. Current trends in computer aided drug design and a highlight of drugs discovered
via computational techniques: A review. European Journal of Medicinal Chemistry, 2021, 224, 113705.
2 Lead-hit-based methods for drug design and ligand identification 47
https://t.me/med1917
[18] Bjelic, S., et al. Computational inhibitor design against malaria plasmepsins. Cellular and Molecular
Life Sciences, 2007, 64, 2285–2305.
[19] Adu-Ampratwum, D., et al. Identification and optimization of a novel HIV-1 integrase inhibitor. ACS
Omega, 2022, 7(5), 4482–4491.
[20] Fader, L. D., et al. Discovery of BI 224436, a noncatalytic site integrase inhibitor (NCINI) of HIV-1.
ACS Medicinal Chemistry Letters, 2014, 5(4), 422–427.
[21] Lv, Y.-X., et al. LSD1 inhibitors for anticancer therapy: A patent review (2017-present). Expert Opinion
on Therapeutic Patents, 2022, 32(9), 1027–1042.
[22] Jiménez-Alberto, A., et al. Virtual screening of approved drugs as potential SARS-CoV-2 main
protease inhibitors. Computational Biology and Chemistry, 2020, 88, 107325.
[23] Erlanson, D. A., Davis, B. J., & Jahnke, W. Fragment-based drug discovery: Advancing fragments in
the absence of crystal structures. Cell Chemical Biology, 2019, 26(1), 9–15.
[24] Li, Q. Application of fragment-based drug discovery to versatile targets. Frontiers in Molecular
Biosciences, 2020, 7, 180.
[25] Kirsch, P., et al. Concepts and core principles of fragment-based drug design. Molecules, 2019,
24(23), 4309.
[26] Konaklieva, M. I., & Plotkin, B. J. Fragment-based lead discovery strategies in antimicrobial drug
discovery. Antibiotics, 2023, 12(2), 315.
[27] Bollag, G., et al. Vemurafenib: The first drug approved for BRAF-mutant cancer. Nature Reviews
Drug Discovery, 2012, 11(11), 873–886.
[28] Velvadapu, V., Farmer, B. T., & Reitz, A. B. Fragment-based drug discovery. In: Camille Georges
Wermuth, David Aldous, Pierre Raboisson, Didier Rognan, (eds) The Practice of Medicinal Chemistry.
2015, (pp. 161–180). Elsevier.
[29] Ahmad, N. M., & Li, J. J. Venetoclax (Venclexta): A BCL‐2 Antagonist for Treating Chronic Lymphocytic
Leukemia. Current Drug Synthesis, 2022, (pp. 143–163) John Wiley & Sons, Inc.
[30] Souers, A. J., et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while
sparing platelets. Nature Medicine, 2013, 19(2), 202–208.
[31] Curtin, N. J. The development of Rucaparib/Rubraca®: A story of the synergy between science and
serendipity. Cancers, 2020, 12(3), 564.
[32] Murray, C. W., Newell, D. R., & Angibaud, P. A successful collaboration between academia, biotech
and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA.
MedChemComm, 2019, 10(9), 1509–1511.
[33] Rahman, A. M., Korashy, H. M., & Kassem, M. G. Gefitinib. Profiles of Drug Substances, Excipients
and Related Methodology, 2014, 39, 239–264.
[34] Prior, M., et al. Back to the future with phenotypic screening. ACS Chemical Neuroscience, 2014, 5(7),
503–513.
[35] Cowan-Jacob, S. W., et al. Structural biology contributions to the discovery of drugs to treat chronic
myelogenous leukaemia. Acta Crystallographica Section D: Biological Crystallography, 2007, 63(1),
80–93.
[36] Duvic, M., & Vu, J. Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on
vorinostat. Biologics: Targets and Therapy, 2007, 1(4), 377–392.
[37] Leonetti, A., et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung
cancer. British Journal of Cancer, 2019, 121(9), 725–737.
[38] Walker, J. S., Garzon, R., & Lapalombella, R. Selinexor for advanced hematologic malignancies.
Leukemia & Lymphoma, 2020, 61(10), 2335–2350.
[39] Lahlou, M. Screening of natural products for drug discovery. Expert Opinion on Drug Discovery,
2007, 2(5), 697–705.
[40] Lahlou, M. The success of natural products in drug discovery. Pharmacology & Pharmacy, 2013,
4(03), 17–31.
48 Gita Chawla and Tathagata Pradhan
https://t.me/med1917
[41] Mahdi, J. G. Medicinal potential of willow: A chemical perspective of aspirin discovery. Journal of
Saudi Chemical Society, 2010, 14(3), 317–322.
[42] Harvey, A. L. Natural products as a screening resource. Current Opinion in Chemical Biology, 2007,
11(5), 480–484.
[43] Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. The re-emergence of natural products for drug
discovery in the genomics era. Nature Reviews Drug Discovery, 2015, 14(2), 111–129.
[44] Phillipson, J. D. Phytochemistry and medicinal plants. Phytochemistry, 2001, 56(3), 237–243.
[45] Grabley, S., & Thiericke, R. Drug Discovery from Nature. 1998, Springer: Verlag Berlin Heidelberg
New York.
[46] Brahmachari, G. Natural products in drug discovery: Impacts and opportunities – An assessment.
In: Goutam Brahmachari, (ed) Bioactive Natural Products: Opportunities and Challenges in
Medicinal Chemistry. 2012, (pp. 1–199). World Scientific.
[47] Dong, M., et al. Novel natural product-and privileged scaffold-based tubulin inhibitors targeting the
colchicine binding site. Molecules, 2016, 21(10), 1375.
[48] Chiba, K. Discovery of fingolimod based on the chemical modification of a natural product from the
fungus, Isaria sinclairii. The Journal of Antibiotics, 2020, 73(10), 666–678.
[49] Newman, D. J., & Cragg, G. M. Natural products as sources of new drugs from 1981 to 2014. Journal
of Natural Products, 2016, 79(3), 629–661.
[50] Neves, B. J., et al. QSAR-based virtual screening: Advances and applications in drug discovery.
Frontiers in Pharmacology, 2018, 9, 1275.
[51] Lo, Y.-C., et al. Machine learning in chemoinformatics and drug discovery. Drug Discovery Today,
2018, 23(8), 1538–1546.
2 Lead-hit-based methods for drug design and ligand identification 49
https://t.me/med1917
https://t.me/med1917
Gagandeep Kaur
✶
, Isha Rani, Prabodh Chander Sharma,
and Diksha Gulati
3 Virtual screening tools
in ligand and receptor-based drug design
Abstract: Virtual screening is a computational technique used in drug design to iden-
tify potential lead compounds that can bind to a target receptor with high affinity and
specificity. There are two types of virtual screening methods used in ligand and recep-
tor-based drug design: ligand-based virtual screening and receptor-based virtual
screening.
Ligand-based virtual screening uses a known ligand or a set of ligands that bind
to the target receptor as a reference. Receptor-based virtual screening, on the other
hand, uses the 3D structure of the target receptor to identify potential ligands.
Virtual screening tools have been widely utilized in drug discovery, and they
have shown promise in identifying active compounds for a variety of therapeutic tar-
gets. However, it is important to perform experimental validation, and the identified
lead compounds must be further tested and optimized through biochemical and phar-
macological assays.
Keywords: Docking, ligands, virtual screening, pharmacological assays, drug discovery
3.1 Introduction
Lead identification, lead optimization, and scaffold hopping are just some of the drug
discovery tasks for which the virtual screening method has been applied extensively. It
is a low-cost, quick alternative to high-throughput screening for finding new medicines.
While the problem of searching the entire chemical universe is intriguing in theory, the
more realistic virtual screening (VS) methodology entails the development of opti-
mized combinatorial databases and the expansion of existing compound libraries,
sourced from either internal repositories or vendor products. Due to the method’s
✶
Corresponding author: Gagandeep Kaur, Chitkara School of Pharmacy, Chitkara University, Solan,
Himachal Pradesh, India, e-mail: gagan17986@gmail.com
Isha Rani, Spurthy College of Pharmacy, Marasur Gate, Bengaluru 562106, Karnataka, India,
e-mail: id-isha12th@gmail.com
Prabodh Chander Sharma, School of Pharmaceutical Sciences, DPSRU, New Delhi,
e-mail: sharma.prabodh@dpsru.edu.in
Diksha Gulati, Guru Gobind Singh College of Pharmacy, Yamunanagar, Haryana,
e-mail: dikshagulatir@gmail.com
https://doi.org/10.1515/9783111207117-003
https://t.me/med1917
growing precision, VS is now routinely used in the discovery of novel pharmaceuticals.
Compounds from an internal database, compounds that can be procured from outside
sources, and compounds that should be synthesized next can all be selected using VS.
The two primary methods for drug design are ligand-based and structure-based ap-
proaches. Ligand-based drug design involves the use of ligand similarity, while
structure-based drug design employs l igand docking techniques. The technique of
protein–ligand docking employs the tridimensional configuration of the target pro-
tein to anticipate the modes and strengths of ligand bindings. Conversely, ligand
similarity approaches exploit the principle that ligands resembling an active ligand
exhibit a higher probability of being active compared to arbitrary ligands [1].
The complexity of the molecular reality of drug–receptor interactions has resulted
in a lack of understanding among experts regarding the feasibility of completely reli-
able in silico technology for drug discovery. The complicated nature of ligand–receptor
interactions is influenced by various factors such as multiple binding modes, accessible
conformational states for both the ligand and the receptor, affinity versus selectivity,
binding to plasma proteins, metabolic stability (site of reactivity and turnover), absorp-
tion, distribution, and excretion, and in vivo versus in vitro properties of model com-
pounds. The formation of carbon–carbon bonds in combinatorial libraries has been
challenging due to the scarcity or absence of synthetic blocks and the varying reactivity
of identical yet diverse reagents, leading to the production of impure or unsynthe-
sized compounds. As a result, lead-finding efforts have focused on the formation of
carbon–heteroatom bonds, resulting in moderately successful combinatorial libraries
[2]. The fields of computational, combinatorial, and medicinal chemistry are becoming
increasingly aware of these technological limitations, which has led to the development
of well-thought-out strategies to address them. In the domain of target-related library
design, it is common practice to employ genetic algorithms or statistical molecular de-
sign for reagent selection in synthesis planning, particularly when three-dimensional
target information is accessible [3]. Permeability and solubility are crucial characteris-
tics that must be present in orally administered compounds. In order to identify poten-
tial leads for further optimization, computational aspects, and experimental methods
are being used to screen for these properties. This approach is becoming increasingly
prevalent [4]. Early optimization of absorption, distribution, metabolism, and excretion
(ADME) during drug discovery is crucial due to its impact on the progression of a drug
candidate toward its commercialization [5].
3.2 Concept of virtual screening
Virtual drug screening is a computational approach that is commonly employed in
the pharmaceutical sector to identify potential therapeutic agents from vast chemical
databases. The primary goal of VS is to reduce the large number of potential therapeu-
52 Gagandeep Kaur et al.
https://t.me/med1917
tic candidates from the enormous virtual chemical data base of small organic mole-
cules that can be either synthesized or screened against a specific target protein [6].
It is a cheap and quick way to narrow down the list of potential substances to test
in the lab.
The concept of “virtual screening” refers to the use of computational algorithms
and molecular modeling tools to predict the binding affinity of a potential drug candi-
date called a ligand to its respective target protein. Using the crystal structure or ho-
mology model of the target protein, a virtual library of prospective compounds can be
created for screening.
The compounds in the virtual library are sourced from either in-house chemical
libraries or databases available for purchase. These libraries may contain millions of
chemicals, making it difficult to conduct in-depth experiments on each one. By using
VS methods, the num ber of potential drug candidates can b e narrowed down to a
manageable level before being subjected to further experimental testing. VS can be
categorized into two approaches: ligand-based and structure-based. The primary
focus of ligand-based VS is on the properties of ligands that are already known to
bind with the target protein. The goal is to identify compounds that display a binding
affinity for the target protein and share structural features with known ligands [7].
The structure-based VS approach is centrally based on the consideration of the
target protein’s three-dimensional structure. The objective is to ascertain and demon-
strate favorable interactions with compounds that exhibit binding affinity towards
the protein. This methodology proves to be advantageous in cases where the confor-
mation of the protein of interest is established, in contrast to the approach of ligand-
based screening.
The efficacy of VS is significantly contingent upon the precision of the computa-
tional algorithms employed to forecast the specific affinity for binding of compounds
to the chosen target protein. It is equally important to perform empirical validation of
the predicted hits to ensure they have the expected biological activity.
When applied to the drug discovery process as a whole, VS is a powerful tool that
can speed up the process and increase the likelihood of success in finding new drug
candidates. It is commonly used in conjunction with other experiment al approaches
to increase the success rate of drug discovery programs [8].
Structure-based VS: Therapeutic candidates are identified in drug development
using a computational method called structure-based VS (SBVS) based on the ability to
bind to a specific protein target [9]. This type of VS makes use of the 3D structure of
the target protein to predict the binding affinity of potential ligands with the tar-
get [10].
Protein synthesis, ligand library construction, dock scoring, and hit validation are
all common SBVS procedures [11]. In order to use SBVS, the structure of the desired
protein must be optimized for the protonation of all ionizable residues and the re-
moval of all crystallographic water molecules and other ligands [12].
3 Virtual screening tools in ligand and receptor-based drug design 53
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана